BiotechTube

AL001 + Placebo + Open label - AL001

Phase 3Terminated
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Frontotemporal Dementia

Conditions

Frontotemporal Dementia

Trial Timeline

Jul 23, 2020 → Jan 6, 2026

NCT ID
NCT04374136

About AL001 + Placebo + Open label - AL001

AL001 + Placebo + Open label - AL001 is a phase 3 stage product being developed by Alector for Frontotemporal Dementia. The current trial status is terminated. This product is registered under clinical trial identifier NCT04374136. Target conditions include Frontotemporal Dementia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04374136Phase 3Terminated

Competing Products

7 competing products in Frontotemporal Dementia

See all competitors
ProductCompanyStageHype Score
AL001AlectorPhase 2
44
LY3884963 + Methylprednisolone + Optional Sirolimus + Optional PrednisoneEli LillyPhase 1/2
41
galantamine hydrobromideJohnson & JohnsonPhase 2
52
memantine hydrochlorideLundbeckPhase 3
74
SyntocinonBrain BiotechPhase 2
44
DNL593 + PlaceboDenali TherapeuticsPhase 1/2
36
PBFT02Passage BioPhase 1/2
33

Other Products from Alector

LatozinemabPhase 3
69
GSK4527226Phase 2
44
GSK4527226Phase 2
44
AL001 + PlaceboPhase 2
44
AL002Phase 2
44